Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing

2024-11-1

Evaluating coronary arteries and predicting MACEs using CCTA in lung cancer patients receiving chemotherapy or chemoradiotherapy

2024-11-1

Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study

2024-11-1

A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors

2024-11-1

Particle arc therapy: Status and potential

2024-10-1

Incidence of alopecia in brain tumour patients treated with pencil scanning proton therapy and validation of existing NTCP models

2024-10-1

Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics

2024-10-1

Deep Inspiration breath Hold facilitates surgical cavity registration on cone beam imaging for Partial breast irradiation

2024-10-1

Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors

2024-10-1

Perceived barriers and facilitators affecting utilisation of radiation therapy services: Scoping review findings – Health professional influences

2024-10-1

Automation of ePROMs in radiation oncology and its impact on patient response and bias

2024-10-1

Non-complete recovery of temporal lobe white matter diffusion metrics at one year Post-Radiotherapy: Implications for Radiation-Induced necrosis risk

2024-10-1

Novel time-synchronized immune-guided partial tumor irradiation: Proof of principle trial

2024-10-1

“Mid-P strategy” versus “internal target volume strategy in locally advanced non small cell lung cancer: Clinical results from the randomized non-comparative phase II study Mid-P

2024-10-1

A T2-weighted MRI-based radiomic signature for disease-free survival in locally advanced cervical cancer following chemoradiation: An international, multicentre study

2024-10-1

Sequence of Contact X-ray Brachytherapy (CXB) and External Beam Radiation (EBRT) in organ-preserving treatment for small rectal cancer

2024-10-1

A probabilistic evaluation of the Dutch robustness and model-based selection protocols for Head-and-Neck IMPT: A multi-institutional study

2024-10-1

Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort

2024-10-1

Secondary cancer risk in six anatomical sites when using PAT, IMPT, and VMAT/IMRT radiotherapy

2024-10-1

Contents

2024-9-4

Aims+Scope/Editorial Board/ Publication information

2024-9-4

Fructose 1,6-bisphosphate aldolase: A promising prognostic marker for oral cancer and its role in radiotherapy response

2024-9-1

Automated dose evaluation on daily cone-beam computed tomography for breast cancer patients

2024-9-1

Physical activity at diagnosis is associated with tumor downstaging after neoadjuvant chemoradiotherapy in patients with rectal cancer

2024-9-1

Lymphocyte radiosensitivity: An extension to the linear-quadratic model?

2024-9-1

Validation and reproducibility of in vivo dosimetry for pencil beam scanned FLASH proton treatment in mice

2024-9-1

Multidisciplinary team quality improves the survival outcomes of locally advanced rectal cancer patients: A post hoc analysis of the STELLAR trial

2024-9-1

Association of the combined stereotactic radiosurgery and embolization strategy and long-term outcomes in brain arteriovenous malformations with a volume >10 ml: A nationwide multicenter observational prospective cohort study

2024-9-1

Brachial plexopathy following stereotactic body radiation therapy in apical lung malignancies: A dosimetric pooled analysis of individual patient data

2024-9-1

Semi-automated reproducible target transfer for cardiac radioablation – A multi-center cross-validation study within the RAVENTA trial

2024-9-1

Recording and reporting of ultra-high dose rate “FLASH” delivery for preclinical and clinical settings

2024-9-1

A patient-specific auto-planning method for MRI-guided adaptive radiotherapy in prostate cancer

2024-9-1

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update

2024-9-1

Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry

2024-9-1

Contents

2024-9-1

Call For Papers: Radiotherapy & Oncology and The Lancet Oncology collaboration

2024-9-1

Fully automated radiotherapy treatment planning: A scan to plan challenge

2024-9-1

Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database

2024-9-1

Challenges and opportunities in the development and clinical implementation of artificial intelligence based synthetic computed tomography for magnetic resonance only radiotherapy

2024-9-1

Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field

2024-9-1

FET PET-based target volume delineation for the radiotherapy of glioblastoma: A pictorial guide to help overcome methodological pitfalls

2024-9-1

Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

2024-9-1

Hypofractionated proton and carbon ion beam radiotherapy for sacrococcygeal chordoma (ISAC): An open label, randomized, stratified, phase II trial

2024-9-1

Concerns regarding the use of only phase 2 study to Justify palliative radiotherapy vs. Palliative chemo-radiotherapy in unresectable head and neck cancer

2024-9-1

Clinical implementation of deep learning robust IMPT planning in oropharyngeal cancer patients: A blinded clinical study

2024-9-1

Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer

2024-9-1

Robustness of intensity modulated proton treatment of esophageal cancer for anatomical changes and breathing motion

2024-9-1

External validation of the lung-molGPA to predict survival in patients treated with stereotactic radiotherapy for brain metastases of non-small cell lung cancer

2024-9-1

FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissection

2024-9-1

GEC-ESTRO recommendations for head & neck cancer brachytherapy (interventional radiotherapy): 2nd update with focus on HDR and PDR

2024-9-1